(NASDAQ: XLO) Xilio Therapeutics's forecast annual revenue growth rate of -53.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.43%.
Xilio Therapeutics's revenue in 2026 is $64,092,000.On average, 2 Wall Street analysts forecast XLO's revenue for 2026 to be $268,029,372, with the lowest XLO revenue forecast at $260,067,387, and the highest XLO revenue forecast at $278,649,739. On average, 2 Wall Street analysts forecast XLO's revenue for 2027 to be $176,315,200, with the lowest XLO revenue forecast at $171,077,398, and the highest XLO revenue forecast at $183,303,322.
In 2028, XLO is forecast to generate $42,402,506 in revenue, with the lowest revenue forecast at $41,139,117 and the highest revenue forecast at $44,080,445.